Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417178 | 0.85 | — | — | |
| SCHEMBL6221243 | 0.75 | SMN1; SMN2 (0.34) | SMN1; SMN2LMNACRBNMMP2MMP9 | |
| SCHEMBL11375741 | 0.75 | CRBN (0.33) | CRBN | |
| SCHEMBL48327 | 0.71 | LMNA (0.36) | SMN1; SMN2LMNACRBNMMP2MMP9 | |
| SCHEMBL28864845 | 0.71 | SMN1; SMN2 (0.32) | SMN1; SMN2LMNACRBNMMP2MMP9 | |
| SCHEMBL29110862 | 0.71 | CRBN (0.31) | CRBN | |
| SCHEMBL2473210 | 0.71 | SMN1; SMN2 (0.32) | SMN1; SMN2LMNACRBNMMP2MMP9 | |
| SCHEMBL29110865 | 0.71 | CRBN (0.31) | CRBN | |
| SCHEMBL24227250 | 0.70 | SMN1; SMN2 (0.31) | SMN1; SMN2LMNACRBN | |
| SCHEMBL4339901 | 0.68 | SMN1; SMN2 (0.30) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1374911-B1 | AGENTS FOR MEASURING PYRIMIDINE METABOLIZABILITY | OTSUKA PHARMA CO LTD (JP) | 2013-10-16 | — | — | EP | claimed |
| EP-2512491-B1 | HBV ANTISENSE INHIBITORS | GLAXO GROUP LTD (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-8883121-B2 | Oral preparation useful in measurement capacity to metabolize pyridine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8598334-B2 | HBV antisense inhibitors | GLAXO GROUP LIMITED (GB) | 2013-12-03 | — | — | US | disclosed |
| EP-2512491-A1 | HBV ANTISENSE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20120207709-A1 | HBV ANTISENSE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| EP-1920786-B1 | ORAL PREPARATION FOR MEASURING PYRIMIDINE METABOLIC CAPACITY | OTSUKA PHARMA CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011047312-A1 | HBV ANTISENSE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| US-20080233048-A1 | Powder by mixing and pulverizing an isotope-labeled uracil, or metabolite labeled with an isotope of carbon atoms, oxygen atoms, or nitrogen atoms and mannitol; time required for the determination and number of measurements can be reduced, decreasing the burden on patients | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1920786-A1 | ORAL PREPARATION USEFUL IN MEASURING CAPACITY TO METABOLIZE PYRIDINE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20030068272-A1 | Preparation for determining pyrimidine metabolic capacity | OTSUKA PHARMACEUTICAL CO., LTD. | 2003-04-10 | — | — | US | disclosed |
| US-4246411-A | ANTICARCINOGENIC AGENTS | PCR INCORPORATED (US) | 1981-01-20 | — | — | US | disclosed |
| US-4029661-A | OR ALCOHOL SOLVENTSFLUORINATION | PCR, INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207709-A1 | HBV ANTISENSE INHIBITORS | HAVCR2, BCDIN3D, HLA-B | SMN1; SMN2 2335/4885LMNA 1497/4885CRBN 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.